36.82 USD
▼-3.43-8.52%
盘后 37.18 +0.98%
2026-09-15
市值
$4.95B
市盈率
—
EPS
-3.48
股息率
—
52 周区间
8.77 – 49.70
成交量
4.53M
Beta
2.24
目标价
71.35
52W 低 8.7752W 高 49.70
价格走势
公司简介
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi...
关联新闻
- First Marijuana, Then Peptides. Why Psychedelics Are Wall Street's Next Big Trip.
Definium Therapeutics advances the case for medical LSD after reporting positive late-stage trial data for its experimental drug, DT120.